breast cancer

AZ
Content Channel

FDA delays ruling on AstraZeneca drug after negative adcomm vote

The FDA deferred its ruling on AstraZeneca’s camizestrant to review analyses filed after an advisory committee voted against the breast cancer asset.
Nick Paul Taylor May 27, 2026 4:43am
Businessman climbing steps to pluck a star from the sky

Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3 study

May 4, 2026 8:06am
AZ

FDA panel rejects AstraZeneca's novel oral SERD proposal

Apr 30, 2026 1:48pm
FDA

FDA flags concerns for AZ's camizestrant, Truqap ahead of adcomm

Apr 28, 2026 2:47pm
Graham
Favicon Fierce Pharma

Roche exec: Giredestrant may become company’s largest product

Apr 23, 2026 2:52pm
Roche headquarers towers Basel

Roche boosts diagnostics offerings with $595M Saga buyout

Apr 20, 2026 8:42am